Pharmaceutical Grade Cancer Treatment Raw Material Dihydroartemisinin Powder CAS 81496-82-4

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: API
• Certification: GMP, ISO 9001, USP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Keyword: CAS 81496-82-4
• Keyword 1: Dihydroartemisinin Powder
• Keyword 2: Dihydroartemisinin
• Sample: Available
• OEM: Available
• MOQ: 10g
• Transport Package: 1kg Foil Bag /25kg Drum
• Specification: 99%
• Trademark: xinlu
• Origin: China
• Production Capacity: 20000

Product Description

 

 

• Chemical Name: (3R,5aS,6R,8aS,9R,12S,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one
• Molecular Weight: 284.35
• Physical Properties: It is a white or off-white crystalline powder. It is slightly soluble in water and easily soluble in organic solvents such as and . It is the main active metabolite of artemisinin and has better antimalarial activity than artemisinin itself.

 

Product Name	High Quality Pharmaceutical Grade Cancer Treatment Raw Material Dihydroartemisinin Powder CAS 81496-82-4
Appearance	White powder
Molecular formula	C15H24O5
Molecular Weight	284.35
Keywords	Dihydroartemisinin Powder;Pharmaceutical Grade Dihydroartemisinin;Purity Dihydroartemisinin
Shelf Life	24 months when properly stored
Storage	Keep in a cool, dry, dark location

1. Antimalarial Mechanism: Dihydroartemisinin mainly acts on the trophozoite stage of the malaria parasite. It contains an endoperoxide bridge structure. In the presence of ferrous ions in the malaria parasite, it is decomposed to generate free radicals. These free radicals can alkylate and damage the membrane structure and proteins of the malaria parasite, especially the membrane of the food vacuole of the malaria parasite, thereby inhibiting the growth and reproduction of the malaria parasite and playing an antimalarial role.
2. First-line Drug: Dihydroartemisinin is a first-line drug for the treatment of malaria, especially for falciparum malaria, which is highly effective against both chloroquine-sensitive and chloroquine-resistant falciparum malaria. It can quickly relieve symptoms such as fever and chills in malaria patients, and significantly reduce the parasitemia in the blood.

1. Combination Therapy: In clinical practice, dihydroartemisinin is often used in combination with other antimalarial drugs to form artemisinin-based combination therapies (ACTs). For example, dihydroartemisinin-piperaquine phosphate tablets are a commonly used combination. The combination therapy can not only improve the curative effect but also reduce the possibility of the malaria parasite developing drug resistance.
2. Other Potential Applications: In addition to its application in the treatment of malaria, some studies have found that dihydroartemisinin has certain inhibitory effects on some tumor cells and may have potential application prospects in the field of oncology. However, this is still in the research and exploration stage and has not been widely used in clinical practice.